Scholars Central

Conference abstractPublished 4 Aug 2015

Treatment of triple negative breast cancer using a tumor membrane based immunotherapy

Authors: Veerendra Koppolu, Christopher Pack, Periasamy Selvaraj

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Triple negative breast cancer (TNBC), which includes tumors lacking estrogen receptor, progesterone receptor, and HER-2 proteins, represents one of the most challenging cancers for developing an effective therapy due to lack of a therapeutic target. Here, we tested an immunotherapy approach that is personalized, easy to accomplish, and not requiring establishment of cell lines or gene transfer to treat metastatic TNBC. The defining principle of this cancer immunotherapy technology is the incorporation of glycolipid-anchored forms of immunostimulatory molecules (GPI-ISMs) onto tumor membrane vesicles (TMV) derived from TNBC mice model. We tested our immunotherapy approach in both therapeutic and prophylactic vaccinations. Therapeutic vaccination of mice after tumor resections increased over all survival in mice receiving TNBC tumor membrane-based immunotherapy. Also, prophylactic vaccination of mice with immunotherapy and antibody based combination therapy showed a reduction in lung metastasis by 90% relative to untreated groups in clonogenic assays. To test whether the observed decrease in metastasis in our combination therapy is due to enhanced CD4 or CD8 T cell specific immune response, we depleted CD4 and CD8 T cells separately using their specific antibodies and performed clonogenic assay. Depletion of CD8 (but not CD4) T cells prior to challenge recapitulated full metastasis, suggesting that immunotherapy induced CD8 T cells specific responses. In summary, we have demonstrated the feasibility of this novel immunotherapy in the triple negative breast cancer model when used in combination with antibody therapy. A reduction in metastasis to the lung, prolonged overall survival, and enhanced CD8 T cell responses were observed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Biotechnology & Biomaterials.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Biotechnology & Biomaterials
  • SubjectBiochemistry & Biotechnology
  • SubjectMaterials Science
  • BylineArticles whose byline prints “Veerendra Koppolu”
  • BylineArticles whose byline prints “Christopher Pack”
  • BylineArticles whose byline prints “Periasamy Selvaraj”